Trandolapril
Trandolapril is a prodrug ACE inhibitor that is hydrolyzed in the liver to its active diacid form trandolaprilat, which inhibits angiotensin-converting enzyme, reducing angiotensin II production and aldosterone secretion, leading to vasodilation and decreased sodium retention. It is approved for hypertension, heart failure post-myocardial infarction, and left ventricular dysfunction after MI, and provides cardioprotective benefits beyond its antihypertensive effects. Its high tissue ACE binding affinity and long duration of action support once-daily dosing.
分子量
430.5000 g/mol
LogP
2.00
TPSA
95.90 Ų
Lipinski 五规则
符合
治疗领域
作用机制
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
二维结构
Cite this structure
Embed this structure
SMILES
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@H]2CCCC[C@@H]21
InChI
InChI=1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1
Molecular Formula
C24H34N2O5
HBD / HBA
2 / 6
可旋转键数
10
重原子数
31
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
常见问题
Trandolapril is a prodrug ACE inhibitor that is hydrolyzed in the liver to its active diacid form trandolaprilat, which inhibits angiotensin-converting enzyme, reducing angiotensin II production and aldosterone secretion, leading to vasodilation and decreased sodium retention. It is approved for hypertension, heart failure post-myocardial infarction, and left ventricular dysfunction after MI, and provides cardioprotective benefits beyond its antihypertensive effects. Its high tissue ACE binding affinity and long duration of action support once-daily dosing.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Trandolapril is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1519. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5484727. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="trandolapril"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/trandolapril/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/trandolapril/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/trandolapril/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="trandolapril"></drugfyi-drug>